Company
Abcuro
Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease
Also known as Abcuro, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Newton, Massachusetts, United States
- Legal name
- Abcuro, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Abcuro is developing its lead product candidate ulviprubart for autoimmune disorders and rare cancers, including inclusion body myositis (IBM), T Cell Large Granular Lymphocytic Leukemia (T-LGLL) and T and NK cell lymphomas.
Funding snapshot
- Total raised
- $266MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $66M2026-08-18
Funding rounds
- Round, 2026
- $66M2026-08-18, Company stated
- Round, 2026
- $39.4M2026-08-07, SEC form D sold, 23 investors
- Series C
- $200M2025-02-12, Company stated
- Round, 2025
- $80M2025-02-07, SEC form D sold, 21 investors
- Round, 2023
- $120M2023-08-11, SEC form D sold, 21 investors
- Round, 2020
- $15.5M2020-06-23, SEC form D sold, 15 investors
- Round, 2018
- $8M2018-11-09, SEC form D sold, 3 investors
- Round, 2016
- $2.2M2016-11-30, SEC form D sold, 4 investors
Products
- Other
- ulviprubart
Loading relationship preview